Key statistics dashboard for MediciNova, Inc. (MNOV). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions.
Stock Data
| Price | $2.52 |
| Market Cap | $124M |
| Beta | 0.61 |
| Exchange | NASDAQ |
| Country | US |
Valuation Multiples
| P/E Ratio | -11.60 |
| Price / Book | 3.33 |
| P/S | 134.75 |
| P/FCF | -0.06 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 42.39% |
| EBIT Margin | -1191.68% |
| EBITDA Margin | -1192.46% |
| Operating Margin | -1287.41% |
| Net Margin | -1168.20% |
Financial Health
| Current Ratio | 8.75 |
| Quick Ratio | 8.75 |
| Cash Ratio | 8.58 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.29% |
| Interest Coverage | 0.00 |
Per-Share Data
| Revenue per share | 0.02 |
| Book Value per share | 0.76 |
| Cash per share | 0.52 |
| FCF per share | -39.15 |
| Tangible Book Value per share | 0.46 |
| Dividend per share | 0.00 |
Related companies: ACRV · BMEA · CBUS · FBIO · IMUX · PMVP · RLMD
Explore sector: Healthcare · Biotechnology
More sections of MNOV: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks